Alembic Pharmaceuticals has achieved a significant milestone in its product portfolio expansion, securing final approval from the United States Food and Drug Administration (USFDA) for Diltiazem Hydrochloride Tablets. This approval marks a notable advancement in the company's cardiovascular therapy offerings.

Key Highlights

Market Impact

The approval of Diltiazem Hydrochloride Tablets is expected to strengthen Alembic Pharmaceuticals' position in the cardiovascular drug market. This development could potentially open up new revenue streams for the company in the U.S. pharmaceutical market.

Stock Performance

Despite this development, Alembic Pharmaceuticals' stock closed lower on the day of the announcement:

The stock's negative performance, both on the day of the announcement and year-to-date, suggests that investors may be considering broader market conditions or other company-specific factors beyond this regulatory approval.

Looking Ahead

While the USFDA approval is a positive development for Alembic Pharmaceuticals, investors and analysts will likely be watching closely to see how this translates into revenue growth and market share. The company's ability to successfully commercialize Diltiazem Hydrochloride Tablets in the U.S. market could be a key factor in its future performance.

Alembic Limited , a diversified company with interests in pharmaceuticals and real estate, has announced its financial results for the second quarter of fiscal year 2026. The company reported a mixed performance with growth in revenue and net profit, despite challenges in certain segments.

Financial Highlights

• Consolidated revenue from operations increased by 5.6% year-over-year to Rs 5,586.00 lakhs in Q2 FY26, compared to Rs 5,291.00 lakhs in Q2 FY25.
• Net profit after tax and share of associate's profit rose by 6.2% to Rs 12,849.00 lakhs, up from Rs 12,102.00 lakhs in the same quarter last year.
• Earnings per share (EPS) improved to Rs 5.00, compared to Rs 4.71 in Q2 FY25.

Segment Performance

Alembic Limited operates in two main business segments:

1. Active Pharmaceutical Ingredients (API) Business
2. Real Estate Business

The segment-wise performance for Q2 FY26 is as follows:

The API business showed significant growth in revenue, while the real estate segment remained relatively stable.

Half-Year Performance

For the first half of FY26:

• Consolidated revenue reached Rs 10,561.00 lakhs, a 1.8% increase from Rs 10,370.00 lakhs in H1 FY25.
• Net profit for the half-year stood at Rs 19,013.00 lakhs, up 7.5% from Rs 17,684.00 lakhs in the corresponding period last year.

Balance Sheet and Cash Flow

As of September 30, 2025:

• Total assets increased to Rs 2,72,689.00 lakhs from Rs 2,50,300.00 lakhs as of March 31, 2025.
• The company maintained a strong equity position with total equity of Rs 2,53,580.00 lakhs.
• Cash and cash equivalents stood at Rs 141.00 lakhs.

Conclusion

Alembic Limited's Q2 FY26 results demonstrate the company's ability to grow its revenue and profitability. The strong performance of the API business offset the relatively flat growth in the real estate segment. Investors may find encouragement in the improved earnings per share and the overall growth in net profit.

As the company moves forward, stakeholders will likely be watching for continued growth in the API segment and potential improvements in the real estate business. The diversified nature of Alembic's operations may provide some buffer against sector-specific challenges in the coming quarters.